GlassScriptPhysician profile
Alexis S Goodridge
NPI 1205464617
$3,886.94
in general payments reported to CMS, 2019-2025
20 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $489 · 2023: $743 · 2024: $1,038 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,953.29 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $465.74 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $290.87 | 2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $261.16 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $217.92 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $131.50 | 2021-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $118.04 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.08 | 2023-2025 | Caplyta |
| Amgen INC. | $78.98 | 2021-2022 | |
| Lilly USA, LLC | $67.79 | 2022-2024 | Mounjaro, Jardiance |
| Neurocrine Biosciences, INC. | $42.95 | 2024-2025 | Ingrezza |
| Exact Sciences Corporation | $33.53 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $28.85 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $18.54 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.33 | 2025 | Spravato |
| Dynavax Technologies Corporation | $17.66 | 2025 | Heplisav-B |
| Pfizer INC. | $14.40 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $13.25 | 2023 | Prehevbrio |
| Sanofi-Aventis U.S. LLC | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Goodridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.